Clinical trials: Transplantation Lung
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05135650
- Testing
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Lung Transplantation
Point-of-care Management of Coagulopathy in Lung Transplantation
Pulmonary transplantation is a very demanding surgical procedure, often accompanied by coagulopathy and severe perioperative bleeding.
- Trial name
- NCT03598907
- Testing
- Fresh frozen plasma
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital, Motol
Disorder Related to Cardiac Transplantation
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
This study investigated whether initiation of everolimus together with reduction of calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal impairment would improve renal function.
- Trial name
- NOCTET (NCT00377962)
- Testing
- Everolimus, Mycophenolic acid (MPA)/azathioprine (AZA), Calcineurin inhibitors (CNI)
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 282 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
Lung Transplant READY Pilot Study
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). More than half of people with CF who die without a lung transplant were never referred for consideration.
- Trial name
- NCT05135156
- Testing
- Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention Control)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Washington
Histiocytosis, Langerhans-cell
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
RATIONALE: Giving a monoclonal antibody, such as alemtuzumab, and chemotherapy drugs, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem…
- Trial name
- NCT00618540
- Testing
- alemtuzumab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Non-Melanoma Skin Carcinoma
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung…
- Trial name
- NCT01480219
- Testing
- voriconazole (Vfend), no voriconazole (Vfend)
- Volunteers
- 467 people
- Sponsor
- Pfizer
Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Despite advances in lung transplantation, the median survival remains only 55% at 5 years. The main limitation to long term survival is the development of chronic lung allograft dysfunction.
- Trial name
- PIRCLAD (NCT03359863)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Lung Preservation
International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation
A prospective, international, multi-center, randomized controlled trial comparing preservation of donor lungs using OCS-Lung perfusion device (Treatment Group) to cold flush and storage (Control Group).
- Trial name
- INSPIRE (NCT01630434)
- Testing
- OCS Lung, Cold flush and storage
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 320 people
- Sponsor
- TransMedics
Chronic Graft-versus-host-disease
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months.
- Trial name
- NCT04200365
- Testing
- Itacitinib
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Atrial Fibrillation, Lung Transplant; Complications
Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients
This study will prospectively evaluate the use of an amiodarone releasing hydrogel applied to the pulmonary veins and atria at the time of lung transplantation.
- Trial name
- NCT03221764
- Testing
- Amiodarone with CoSeal, CO2 driver
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Pneumonia, Idiopathic Pneumonia Syndrome
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
The study is designed as a Phase III, multi-center randomized, double-blind, placebo-controlled trial investigating the use of etanercept for the treatment of acute, non-infectious pulmonary dysfunction (IPS) occurring after…
- Trial name
- NCT00421174
- Testing
- Etanercept
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Brain Death, Organ Donor
The Effect of Nebulized Albuterol on Donor Oxygenation
The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation…
- Conditions
- Brain Death, Organ Donor, Pulmonary Edema
- Trial name
- NCT00310401
- Testing
- Albuterol, Saline
- Where
- United States
- Volunteers
- 506 people
- Sponsor
- Vanderbilt University Medical Center
Transplantation, Lung
Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients.
- Trial name
- TANGELA (NCT02278952)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
The objective of this trial was to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in double lung transplant (DLT) recipients…
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications
- Trial name
- BOSTON-2 (NCT03656926)
- Testing
- Liposomal Cyclosporine A, Standard of Care
- Where
- 40 sites in United States, Austria and 7 more
- Volunteers
- 169 people
- Sponsor
- Zambon SpA
Bronchiolitis
Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status
The goal of this clinical research study is to compare lung function of patients who inhale steroids in the early stages of post-transplant constrictive bronchiolitis (PTCB) to patients who continue with standard of care.
- Trial name
- NCT00656916
- Testing
- Fluticasone Propionate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Ischemia-Reperfusion Injury, Lung Transplantation
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved…
- Trial name
- NCT00224406
- Testing
- Repertaxin
- Where
- 6 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Dompé Farmaceutici S.p.A
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis, Lung Transplant
Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Lung transplantation is a life saving procedure for patients with a terminal lung disease such as cystic fibrosis. Approximately, one in 3,500 children in the United States are born with cystic fibrosis each year with the…
- Trial name
- NCT00908830
- Volunteers
- 10 people
- Sponsor
- University of Michigan
COVID-19, Kidney Transplant
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using…
- Trial name
- CPAT-SG (NCT05518487)
- Testing
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)